Metagenomi Inc (NASDAQ: MGX)’s stock price has soared by 13.02% in relation to previous closing price of $1.69. Nevertheless, the company has seen a gain of 29.05% in its stock price over the last five trading days. globenewswire.com reported 2025-05-14 that – Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders –
Is It Worth Investing in Metagenomi Inc (NASDAQ: MGX) Right Now?
Additionally, the 36-month beta value for MGX is -0.49. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for MGX is 21.80M and currently, short sellers hold a 9.61% ratio of that float. The average trading volume of MGX on July 09, 2025 was 449.22K shares.
MGX’s Market Performance
MGX’s stock has seen a 29.05% increase for the week, with a 15.06% rise in the past month and a 35.46% gain in the past quarter. The volatility ratio for the week is 9.56%, and the volatility levels for the past 30 days are at 8.76% for Metagenomi Inc The simple moving average for the past 20 days is 23.68% for MGX’s stock, with a -9.80% simple moving average for the past 200 days.
Analysts’ Opinion of MGX
Many brokerage firms have already submitted their reports for MGX stocks, with H.C. Wainwright repeating the rating for MGX by listing it as a “Buy.” The predicted price for MGX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on May 07, 2024 of the previous year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see MGX reach a price target of $6, previously predicting the price at $16. The rating they have provided for MGX stocks is “Neutral” according to the report published on May 02nd, 2024.
Wells Fargo gave a rating of “Overweight” to MGX, setting the target price at $25 in the report published on March 05th of the previous year.
MGX Trading at 19.39% from the 50-Day Moving Average
After a stumble in the market that brought MGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.27% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MGX starting from Wein Matthew, who sale 199 shares at the price of $1.75 back on Jun 06 ’25. After this action, Wein Matthew now owns 16,693 shares of Metagenomi Inc, valued at $348 using the latest closing price.
Noonberg Sarah B., the Chief Medical Officer of Metagenomi Inc, sale 5,239 shares at $1.75 during a trade that took place back on Jun 06 ’25, which means that Noonberg Sarah B. is holding 109,135 shares at $9,168 based on the most recent closing price.
Stock Fundamentals for MGX
Current profitability levels for the company are sitting at:
- -1.94 for the present operating margin
- 1.0 for the gross margin
The net margin for Metagenomi Inc stands at -1.72. The total capital return value is set at -0.34. Equity return is now at value -31.93, with -21.86 for asset returns.
Based on Metagenomi Inc (MGX), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at -2.3.
Currently, EBITDA for the company is -83.49 million with net debt to EBITDA at -0.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.91. The receivables turnover for the company is 44.73for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.85.
Conclusion
In conclusion, Metagenomi Inc (MGX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
